Skip to content
Screener

Pelthos Therapeutics PTHS Q1 2026 earnings

Reported May 14, 2026 · Before market open

Revenue$10.9MBeat by $468.3K
EPS-$3.09Beat by $0.36
Revenue estimate$10.4M
EPS estimate-$3.45

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$18.0M
EPS estimate-$2.90

Financials

Q1 2026

Income statement

See full
Revenue$10.9M—
Gross profit$9.2M—
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M—
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K—
Free cash flow-$13.3M-2,008%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$70.5M—
Enterprise value$68.17M—
P/S2.5×—

Profitability

See full
Gross margin79.6%—
Operating margin-157.7%—
Net margin-186.2%—

Returns & leverage

See full
Debt / equity0.8×—
Current ratio2.8×+2.6×

Segments

By segment

See full
Commercial operations$10.7M—
Research and Development operations$241.0K—

FAQ

When did Pelthos Therapeutics report Q1 2026 earnings?
Pelthos Therapeutics (PTHS) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Pelthos Therapeutics's Q1 2026 revenue and EPS?
Pelthos Therapeutics reported revenue of $10.9M and eps of $-3.09 for Q1 2026.
Did Pelthos Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $10.4M by $468.3K. EPS beat the consensus estimate of $-3.45 by $0.36.
Where can I find Pelthos Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001919246-26-000071) and the 10-Q periodic report (0001919246-26-000070) directly on SEC EDGAR. The filing index links above go to sec.gov.